Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 18

recruiting
3 987
countries
28
conditions
2 109

1 221 trials match your criteria

A Study Testing ACP-204 Tartrate Compared to Placebo for Adults with Lewy Body Dementia Psychosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ACP-204 tartrate

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mezagitamab

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303

Study of BNT326 alone and with BNT327 in patients with advanced solid tumors: Testing safety and effectiveness of new cancer treatments

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT326

Study of KarXT (trospium chloride and xanomeline tartrate) and KarX-EC (xanomeline tartrate) for cognitive impairment in mild to moderate Alzheimer's disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trospium Chloride

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Study of IMVT-1402 in Adults with Mild to Severe Generalized Myasthenia Gravis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart

Study of toripalimab, cisplatin and gemcitabine combination as first treatment for patients with recurrent or metastatic nasopharyngeal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.